Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Stroke is a leading cause of death and long-term disability in industrialized countries. Despite advances in understanding its pathophysiology, little progress has been made in the treatment of stroke. The currently available therapies have proven to be highly unsatisfactory (except thrombolysis) and attempts are being made to identify and characterize signaling proteins which could be exploited to design novel therapeutic modalities. The peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that control lipid and glucose metabolism. PPARs regulate gene expression by binding with the retinoid X receptor (RXR) as a heterodimeric partner to specific DNA sequences, termed PPAR response elements. In addition, PPARs may modulate gene transcription also by directly interfering with other transcription factor pathways in a DNA-binding independent manner. To date, three different PPAR isoforms, designated α, β/ δ, and γ, have been identified. Recently, they have been found to play an important role for the pathogenesis of various disorders of the central nervous system and accumulating data suggest that PPARs may serve as potential targets for treating ischemic stroke. Activation of all PPAR isoforms, but especially of PPAR γ, was shown to prevent post-ischemic inflammation and neuronal damage in several in vitro and in vivo models, negatively regulating the expression of genes induced by ischemia/ reperfusion (I/R). This paper reviews the evidence and recent developments relating to the potential therapeutic effects of PPAR-agonists in the treatment of cerebral I/R injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Pathobiology of ischaemic stroke: an integrated view
Dirnagl, U., Iadecola, C., & Moskowitz, M. A. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01401-0 · Cited by 3,943
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · cited 1×
“However, clinical trials have failed to show an increase in cancer diagnoses between treatment groups (Keech et al., 2005; Rubins et al., 1999).”
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Forman, B. M., Chen, J., & Evans, R. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4312 · Cited by 2,116
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 7×
“…available TZDs, rosiglitazone and pioglitazone, were approved in the United States in 1999 and are currently used alone or in combination with other oral anti-diabetic agents for type-2 diabetes patients (Willson et al, 2000; Theocharis et al., 2003; Theocharis et al., 2004; Margeli et al, 2003).”
InfluentialA unified nomenclature system for the nuclear receptor superfamily
(1999) · Cell · doi:10.1016/s0092-8674(00)80726-6 · Cited by 1,208 · cited 1×
“…(AF)-2 (Fajas et al., 1997), and is able to interact with transcriptional coactivators such as steroid receptor coactivator (SRC)- 1 (Kalkhoven et al. 1998; Krey et al., 1997; Onate et al., 1995) and CREB-binding protein (CBP) (Chakravarti et al., 1996; Dowell et al., 1997; Kamei et al., 1996).”
Schoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Molecular recognition of fatty acids by peroxisome proliferator-activated receptors
Xu, H. E., Lambert, M. H., Montana, V. G., Parks, D. J., Blanchard, S. G., Brown, P. J., Sternbach, D. D., Lehmann, J. M., Wisely, G. B., Willson, T. M., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80467-0 · Cited by 1,169
Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069 · cited 1×
“Besides, it is important to note that 15d-PGJ2 can induce a variety of PPAR- independent responses, and 15d-PGJ2 has indeed been shown to induce responses in cells devoid of the receptor (Chawla et al., 2001).”
Chinetti, G., Fruchart, J.-C., & Staels, B. (2000) · Inflammation Research · doi:10.1007/s000110050622 · Cited by 954 · cited 1×
“…found in adipocytes and in cells of the immune system such as monocytes/ macrophages, B and T cells, and dendritic cells (Braissant et al., 1996; Chinetti et al., 1998; Chinetti et al., 2000; Clark et al., 2000; Faveeuw et al., 2000; Gosset et al., 2001; Marx et al., 1998; Yang et al., 2000).”
Feige, J. N., Gelman, L., Michalik, L., Desvergne, B., & Wahli, W. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2005.12.002 · Cited by 786 · cited 2×
“…eicosanoids such as 8-S-hydroxyeicosatetraenoic acid (8-S-HETE), leukotriene B 4 (LTB 4 ) and arachidonate monooxygenase metabolite epoxyeicosatrienoic acids have been shown to potently activate PPAR- with high affinity (Willson et al., 2000; Feige et al., 2006; Theocharis et al., 2004).”
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods
Buse, J. B. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.003 · Cited by 661
Ghisletti, S., Huang, W., Ogawa, S., Pascual, G., Lin, M.-E., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.11.022 · Cited by 561 · cited 2×
“Other studies have proposed that PPAR-γ may mediate transrepression of a subset of inflammatory response genes in macrophages by preventing the signaldependent clearance of co-repressor complexes on inflammatory promoters downstream of LPS signaling [Ghisletti et al. 2007; Pascual et al. 2005].”
Thiazolidinediones, Like Metformin, Inhibit Respiratory Complex I
Brunmair, B., Staniek, K., Gras, F., Scharf, N., Althaym, A., Clara, R., Roden, M., Gnaiger, E., Nohl, H., Waldhäusl, W., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.4.1052 · Cited by 521
Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
Sacco, R. L., Benson, R. T., Kargman, D. E., Boden-Albala, B., Tuck, C., Lin, I.-F., Cheng, J. F., Paik, M. C., Shea, S., & Berglund, L. (2001) · JAMA · doi:10.1001/jama.285.21.2729 · Cited by 311
Yue, T.-L., Chen, J., Bao, W., Narayanan, P. K., Bril, A., Jiang, W., Lysko, P. G., Gu, J.-L., Boyce, R., Zimmerman, D. M., et al. (2001) · Circulation · doi:10.1161/hc4601.099403 · Cited by 295 · cited 1×
“A role for PPARs in reducing I/R injury has been first established in animal models of acute myocardial infarction (Yue et al., 2001; Wayman et al., 2002).”
Leppälä, J. M., Virtamo, J., Fogelholm, R., Albanes, D., & Heinonen, O. P. (1999) · Stroke · doi:10.1161/01.str.30.12.2535 · Cited by 272 · cited 1×
“It is of interest to note that increased expression of lipoprotein lipase, which is known PPAR-α target gene, in skeletal muscle leads to severe myopathy in mice (Levak-Frank et al., 1995; Schoonjans et al., 1996).”
Bernardo, A., Levi, G., & Minghetti, L. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00110.x · Cited by 222 · cited 1×
“PPAR- is constitutively expressed in macrophages and microglial cells (Bernardo et al., 2000) and the systemic treatment of rodents with rosiglitazone reduces the infiltration of these cells into peri-infarct brain regions (Luo et al., 2006; Sundararajan et al., 2005).”
A Paradigm for Gene Regulation: Inflammation, NF-κB and PPAR
Vanden Berghe, W., Vermeulen, L., Delerive, P., De Bosscher, K., Staels, B., & Haegeman, G. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-9072-3_22 · Cited by 222 · cited 3×
“…addition, PPAR-α ligands, induce the expression of the inhibitory protein inhibitor of kappa B (IκB)α in smooth muscle cells and hepatocytes, which sequesters the NF-κB subunits in the cytoplasm and consequently reduces their DNA binding activity (Delerive et al., 2000; Vanden Berghe et al., 2003).”
Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C., Ramrakhiani, S., Quiason, S. G., Phillips, N. J., & Brunt, E. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00009 · Cited by 195
Tanne, D., Koren-Morag, N., Graff, E., & Goldbourt, U. (2001) · Circulation · doi:10.1161/hc4901.100384 · Cited by 158
Cited by
Deb, P., Sharma, S., & Hassan, K. M. (2010) · Pathophysiology · doi:10.1016/j.pathophys.2009.12.001 · Cited by 562
Adibhatla, R. M., & Hatcher, J. F. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2668 · Cited by 480
Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation
Villapol, S. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0554-5 · Cited by 369
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease
Corona, J. C., & Duchen, M. R. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.06.023 · Cited by 259
Metadata
- Authors
- Collino, M., Patel, N. S. A., & Thiemermann, C.
- Venue
- Therapeutic Advances in Cardiovascular Disease
- Publisher
- SAGE Publications
- Published
- 2008-06
- Volume
- 2
- Issue
- 3
- Pages
- 179-197
- ISSN
- 1753-9447 (ISSN-L)
- 1753-9455
- OpenAlex
- W2028775513
- Cited by
- 86
- References
- 28
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.